Allegra, C, Jessup, JM, Somerfield, MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutati-ons in patients with metastatic colorectal carcinoma to predict res-ponse to anti-epidermal growth factor receptor monoclonal antibody therapy. Journal of Clinical Oncology. 2009;epub JCO.2009.21.9170.

Amado, RG, Wolf, M, Peeters, M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(10):1626–1634.CrossRefGoogle ScholarPubMed

Bair, E, Tibshirani, R.Semi-supervised methods to predict patient survival from gene expression data. PLoS Biology. 2004;2:511–522.CrossRefGoogle ScholarPubMed

Beckman, RA, Clark, J, Chen, C. Integrating predictive biomarkers and classifiers into oncology clinical development programs. Nature Re-views Drug Discovery. 2011;10:735–748.CrossRefGoogle Scholar

Ben-Dor, A, Bruhn, L, Friedman, N, Nachman, I, Schummer, M, Yakhini, Z. Tissue classification with gene expression profiles. Journal of Computational Biology. 2000;7:559–584.CrossRefGoogle ScholarPubMed

Berger, JO. Statistical Decision Theory and Bayesian Analysis. New York: Springer; 2010.Google Scholar

Bo, TH, Jonassen, I.New feature subset selection procedures for classification of expression profiles. Genome Biology. 2002;3(4):0017.1–0017.11.CrossRefGoogle ScholarPubMed

Bogaerts, J, Cardoso, F, Buyse, M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice: Oncology. 2006;3(10):540–551.CrossRefGoogle ScholarPubMed

Bovelstad, HM, Nygard, S, Storvold, HL, et al. Predicting survival from microarray data – a comparative study. Bioinformatics. 2007;23(16):2080–2087.CrossRefGoogle ScholarPubMed

Cai, T, Tian, L, Wong, PH, Wei, LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011;12:270–282.CrossRefGoogle ScholarPubMed

Cook, NR.Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–935.CrossRefGoogle ScholarPubMed

Cox, DR.Regression models and life-tables. Journal of the Royal Statistical Society B. 1972;34:187–220.Google Scholar

Cox, DR, Snell, EJAnalysis of Binary Data. Boca Raton FL, Chapman and Hall/CRC; 1989.Google Scholar

Cronin, M, Sangli, C, Liu, M-L, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical Chemistry. 2007;53(6):1084–1091.CrossRefGoogle ScholarPubMed

Crowley, J, Hoering, A eds. Handbook of Statistics in Clinical Oncology, 3rd ed. Boca Raton, FL: Chapman Hall/CRC; 2012.Google Scholar

Deutsch, JM. Evolutionary algorithms for finding optimal gene sets in microarray prediction. Bioinformatics. 2003;19:45–54.CrossRefGoogle ScholarPubMed

Dobbin, K, Simon, R.Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics. 2005;6:27–38.CrossRefGoogle ScholarPubMed

Dobbin, K, Simon, R. Sample size planning for developing classifiers using high dimensional DNA expression data. Biostatistics. 2007;8:101–117.CrossRefGoogle Scholar

Dobbin, K, Simon, ROptimally splitting cases for training and testing high dimensional classifiers. BMC Medical Genomics. 2011;4:31.CrossRefGoogle ScholarPubMed

Dobbin, KK, Zhao, Y, Simon, RM. How large a training set is needed to develop a classifier for microarray data?Clinical Cancer Research. 2008;14:108–114.CrossRefGoogle Scholar

Dudoit, S, Fridlyand, J. Classification in microarray experiments. In: Speed, T, ed. Statistical Analysis of Gene Expression Microarray Data. Boca Raton, FL: Chapman and Hall/CRC; 2003:93–158.Google Scholar

Dudoit, S, Fridlyand, J, Speed, TP. Comparison of discrimination methods for the classification of tumors using gene expression data. Journal of the American Statistical Association. 2002;97:77–87.CrossRefGoogle Scholar

Dupuy, A, Simon, R. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. Journal of the National Cancer Institute. 2007;99:147–157.CrossRefGoogle ScholarPubMed

Ellenberg, S, Fleming, TR, DeMets, D. Data Monitoring Committees in Clinical Trials: A Practical Perspective. New York: Wiley; 2002.CrossRefGoogle Scholar

Fisher, RA. The use of multiple measurements in taxonomic problems. Annals of Eugenics. 1936;7:179–188.CrossRefGoogle Scholar

Fleming, TR.Interpretation of subgroup analyses in clinical trials. Drug Information Journal. 1995;29:1681S–1687S.CrossRefGoogle Scholar

Fleming, TR, Watelet, L. Approaches to monitoring clinical trials. Journal of the National Cancer Institute. 1989;188–193.

Foster, JC, Taylor, JMG, Ruberg, SJ. Subgroup identification from randomized clinical trial data. Statistics in Medicine. 2011;30:2867–2880.CrossRefGoogle ScholarPubMed

Fox, E, Curt, GA, Balis, FM. Clinical trial design for target-based therapy. The Oncologist 2002;7:401–409.CrossRefGoogle ScholarPubMed

Freidlin, B, Jiang, W, Simon, R. The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research. 2010;16(2):691–698.CrossRefGoogle Scholar

Freidlin, B, McShane, LM, Korn, EL. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute. 2010;102(3):152–160.CrossRefGoogle ScholarPubMed

Freidlin, B, Simon, R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research. 2005;11:7872–7878.CrossRefGoogle ScholarPubMed

Freidlin, B, McShane, LM, Polley, MY, Korn, EL. Randomized phase II trial designs with biomarkers. Journal of Clinical Oncology. 2012;30(30):3304–3309.CrossRefGoogle ScholarPubMed

Golub, TR, Slonim, DK, Tamayo, P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537.CrossRefGoogle ScholarPubMed

Green, S, Benedetti, J, Crowley, J.Clinical Trials in Oncology. 2nd ed. Boca Raton FL: Chapman and Hall/CRC; 2003.Google Scholar

Harrell, FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer; 2001.Google Scholar

Hastie, T, Tibshirani, R, Eisen, M, et al. Gene shaving as a method for identifying distinct sets of genes with similar expression patterns. Genome Biology. 2000;1(2)3.1–3.21.CrossRefGoogle ScholarPubMed

Hastie, T, Tibshirani, R, Friedman, J.The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd ed. New York: Springer; 2009.CrossRefGoogle Scholar

Haybittle, JL.Repeated assessment of results in clinical trials of cancer treatment. Journal of Radiology. 1971;44:793.CrossRefGoogle ScholarPubMed

Hayes, DF, Bast, RC, Desch, CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute. 1996;88:1456–1466.CrossRefGoogle ScholarPubMed

Heagerty, PJ, Lumley, T, Pepe, MS. Time dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–344.CrossRefGoogle Scholar

Hess, KR, Anderson, K, Symmans, WF, et al. Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-flurouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology. 2006;24(26):4236–4244.CrossRefGoogle Scholar

Hoering, A, LeBlanc, M, Crowley, JJ.Randomized phase III clinical trial designs for targeted agents. Clinical Cancer Research. 2008;14:4358–4367.CrossRefGoogle ScholarPubMed

Hsieh, FY, Lavori, PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates, Controlled Clinical Trials. 2000;21:552–560.CrossRefGoogle ScholarPubMed

Hunsberger, S, Zhao, Y, Simon, R. A comparison of phase II study strategies. Clinical Cancer Research. 2009;15(19):5950–5955.CrossRefGoogle ScholarPubMed

Jennison, C, Turnbull, BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall; 1999.Google Scholar

Jiang, W, Freidlin, B, Simon, R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute. 2007;99:1036–1043.CrossRefGoogle ScholarPubMed

Jones, CL, Holmgren, E. An adaptive Simon two-stage design for phase 2 studies of targeted therapies. Contemporary Clinical Trials. 2007;28:654–666.CrossRefGoogle ScholarPubMed

Kalbfleisch, JD, Prentice, RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 2002.CrossRefGoogle Scholar

Kaplan, EI, Meier, P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457–481.CrossRefGoogle Scholar

Karapetis, CS, Khambata-Ford, S, Jonker, DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine. 2008;359(17):1757–1765.CrossRefGoogle ScholarPubMed

Karuri, S, Simon, R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Statistics in Medicine. 2012;31(10):901–914.CrossRefGoogle ScholarPubMed

Kattan, MW. Judging new markers by their ability to improve predictive accuracy. Journal of the National Cancer Institute. 2003;95(9):634–635.CrossRefGoogle ScholarPubMed

Kattan, MW. Evaluating a new marker's predictive contribution. Clinical Cancer Research. 2004;10:822–824.CrossRefGoogle ScholarPubMed

Khan, J, Wei, JS, Ringner, M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine. 2001;7:673–679.CrossRefGoogle ScholarPubMed

Kim, KI, Simon, R. Probabilistic classifiers with high dimensional data. Biostatistics. 2011;12(3):399–412.CrossRefGoogle ScholarPubMed

Korn, EL, Freidlin, B. Outcome-adaptive randomization: is it useful?Journal of Clinical Oncology. 2011;29:771–776.CrossRefGoogle ScholarPubMed

Korn, EL, Freidlin, B, Abrams, JS, Halabi, S. Design issues in randomized phase II/III trials. Journal of Clinical Oncology. 2012;30(6):667–671.CrossRefGoogle ScholarPubMed

Lai, TL, Lavori, PW, Shih, M, Sikic, BI. Clinical trial designs for testing biomarker-based personalized therapies. Clinical Trials. 2012;9:141–154.CrossRefGoogle ScholarPubMed

Lai, C, Reindders, MJT, van't Veer, LJ, Wessels, LFA. A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. BMC Bioinformatics. 2006;7:235.CrossRefGoogle ScholarPubMed

Lenz, G, Wright, GW, Dave, SS, et al. Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine. 2008;359(22):2313–2323.CrossRefGoogle ScholarPubMed

Li, H, Gui, J. Partial Cox regression analysis for high-dimensional microarray gene expression data. Bioinformatics. 2004;20:i208–i215.CrossRefGoogle ScholarPubMed

Liu, A, Li, Q, Yu, KF, Yuan, VW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clinical Trials. 2010;7(5):537–545.CrossRefGoogle Scholar

Maitournam, A, Simon, ROn the efficiency of targeted clinical trials. Statistics in Medicine. 2005;24:329–339.CrossRefGoogle ScholarPubMed

Mandrekar, SJ, Sargent, DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. Journal of Clinical Oncology. 2009;27:4027–4034.CrossRefGoogle ScholarPubMed

Mandrekar, SJ, Sargent, DJ. Predictive biomarker validation in practice: lessons from real trials. Clinical Trials. 2010;7:567–573.CrossRefGoogle ScholarPubMed

Mantel, N.Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Journal of American Statistical Association. 1963;58:690–700.Google Scholar

Marubini, E, Valsecchi, MG. Analysing Survival Data from Clinical Trials and Observational Studies. New York: Wiley; 1995.Google Scholar

Matsui, S, Simon, R, Qu, P, Shaughnessy, JD, Barlogie, B, Crowley, JJ. Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clinical Cancer Research. 2012; 18(21):6065--6073.

McShane, LM, Hunsberger, S, Adjei, AA. Effective incorporation of bio-markers into phase II trials. Clinical Cancer Research. 2009;15(6):1898–1905.CrossRefGoogle Scholar

Molinaro, AM, Simon, R, Pfeiffer, RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics. 2005;21(15):3301–3307.CrossRefGoogle ScholarPubMed

Nguyen, DV, Rocke, DM. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics. 2002;18:1625–1632.CrossRefGoogle ScholarPubMed

O’Brien, PC, Fleming, TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556.CrossRefGoogle ScholarPubMed

Ooi, CH, Tan, P. Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics. 2003;19:37–44.CrossRefGoogle ScholarPubMed

Paik, S, Shak, S, Tang, G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine. 2004;351:2817–2826.CrossRefGoogle ScholarPubMed

Park, PJ, Tian, L, Kohane, IS. Linking gene expression data with patient survival times using partial least squares. Bioinformatics. 2002;18:S120–S127.CrossRefGoogle ScholarPubMed

Pepe, MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press; 2004.Google Scholar

Pepe, MS, Janes, H, Longton, G, Leisenring, W, Newcomb, P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic or screening marker. American Journal of Epidemiology. 2004;159:882–890.CrossRefGoogle ScholarPubMed

Pepe, MS, Feng, Z, Janes, H, Bossuyt, PM, Potter, JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. Journal of the National Cancer Institute. 2008;100(20):1432–1438.CrossRefGoogle ScholarPubMed

Peterson, B, George, SL. Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome. Controlled Clinical Trials. 1993;14:511–522.CrossRefGoogle Scholar

Peto, R, Pike, MC, Armitage, P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. British Journal of Cancer. 1977;35:1–39.CrossRefGoogle ScholarPubMed

Piantadosi, S. Clinical Trials: A Methodologic Perspective. New York, Wiley; 2005.CrossRefGoogle Scholar

Pocock, SJ. Interim analyses for randomized clinical trials. Biometrics. 1982;39:153.CrossRefGoogle Scholar

Pocock, SJ, Assmann, SE, Enos, LE, Kasten, LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine. 2002;21:2917–2930.CrossRefGoogle ScholarPubMed

Pusztai, L.Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics. 2004;5(5):451–454.CrossRefGoogle Scholar

Pusztai, L, Anderson, K, Hess, KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clinical Cancer Research. 2007;13:6080–6086.CrossRefGoogle ScholarPubMed

Radmacher, MD, McShane, LM, Simon, R. A paradigm for class prediction using gene expression profiles. Journal of Computational Biology. 2002;9:505–512.CrossRefGoogle ScholarPubMed

Rosenwald, A, Wright, G, Chan, WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine. 2002;346:1937–1947.CrossRefGoogle ScholarPubMed

Rubin, DB. Bayesian Data Analysis. Boca Raton FL, Chapman and Hall/CRC; 2009.Google Scholar

Rubin, DB, van der Laan, MJ. Statistical issues and limitations in personalized medicine research with clinical trials. The International Journal of Biostatistics. 2012;8:1–37.CrossRefGoogle ScholarPubMed

Sargent, DJ, Conley, BA, Allegra, C, Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology. 2005;23(9):2020–2027.CrossRefGoogle ScholarPubMed

Sawyers, CL. The cancer biomarker problem. Nature. 2008;452:548–552.CrossRefGoogle ScholarPubMed

Shedden, K, Taylor, JMG, Enkemann, SA, et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 2008;14(8):822–827.CrossRefGoogle ScholarPubMed

Sher, HI, Nasso, SF, Rubin, E, Simon, R. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clinical Cancer Research. 2011;17:6134–6140.Google Scholar

Simon, R.Confidence intervals for reporting results from clinical trials. Annals of Internal Medicine. 1986;105:429–435.CrossRefGoogle ScholarPubMed

Simon, R.Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials. 1989;10:1–10.CrossRefGoogle ScholarPubMed

Simon, RM, Korn, EL, McShane, LM, et al. Design and Analysis of DNA Microarray Investigations. New York: Springer; 2004.Google Scholar

Simon, R, Lam, A, Li, MC, Ngan, M, Menezes, S, Zhao, Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Informatics. 2007;2:11–17.Google Scholar

Simon, R.Using genomics in clinical trial design. Clinical Cancer Research. 2008b;14:5984–5993.CrossRefGoogle ScholarPubMed

Simon, R.Design and analysis of clinical trials. In: DeVita, VT, DePinto, RA, Lawrence, TS, Rosenberg, SA, Weinberg, RA, eds. Principles and Practice of Oncology. 9th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2011:Chapter 70.Google Scholar

Simon, R. Clinical trials for predictive medicine. Statistics in Medicine. In press.

Simon, R, Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research. 2005;10:6759–6763.CrossRefGoogle Scholar

Simon, R, Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clinical Cancer Research. 2006;12:3229.Google Scholar

Simon, RM, Paik, S, Hayes, DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute. 2009;101(21):1–7.CrossRefGoogle ScholarPubMed

Simon, R, Radmacher, MD, Dobbin, K, McShane, LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. Journal of the National Cancer Institute. 2003;95:14–18.CrossRefGoogle ScholarPubMed

Simon, RM, Subramanian, J, Li, MC, Menezes, S. Using cross validation to evaluate prediction accuracy of survival risk classifiers based on high dimensional data. Briefings in Bioinformatics. 2011;12(3):203–214.CrossRefGoogle ScholarPubMed

Simon, R, Wang, SJ. Use of genomic signatures in therapeutics development. The Pharmacogenomics Journal. 2006;6:1667–1173.CrossRefGoogle ScholarPubMed

Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001;344(11):783–792.CrossRefGoogle Scholar

Smith, M, Ungerleider, R, Korn, E, Rubinstein, L, Simon, R. The role of independent data monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. Journal of Clinical Oncology. 1997;15:2736–2743.CrossRefGoogle ScholarPubMed

Song, Y, Chi, GYH. A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine. 2007;26:3535–3549.CrossRefGoogle ScholarPubMed

Sparano, JA, Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology. 2008;26(5):721–728.CrossRefGoogle ScholarPubMed

Speed, T, ed. Statistical Analysis of Gene Expression Microarray Data. Boca Raton, FL: Chapman and Hall/CRC; 2003.CrossRefGoogle Scholar

Spiegelhalter, DJ, Freedman, LS, Parmar, MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society A. 1994;157:357–387.CrossRefGoogle Scholar

Subramanian, J, Simon, R. An evaluation of resampling methods for assessment of survival risk prediction in high dimensional settings. Statistics in Medicine. 2011;30(6):642–653.CrossRefGoogle ScholarPubMed

Subramanian, J, Simon, R. Gene expression-based prognostic signatures in lung cancer: Ready for clinical use?Journal of the National Cancer Institute. 2010a;102:464–474.CrossRefGoogle ScholarPubMed

Subramanian, J, Simon, R.What should physician look for in evaluating prognostic gene expression signatures. Nature Reviews Clinical Oncology. 2010b;7:327–334.CrossRefGoogle ScholarPubMed

Taylor, JMG, Ankerst, DP, Andridge, RR. Validation in biomarker based risk prediction models. Clinical Cancer Research. 2008;14:5977–5983.CrossRefGoogle ScholarPubMed

Tibshirani, R.The lasso method for variable selection in the Cox model. Statistics in Medicine. 1997;16:385–395.3.0.CO;2-3>CrossRefGoogle ScholarPubMed

Tibshirani, R, Hastie, T, Narasimhan, B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:6567–6572.CrossRefGoogle ScholarPubMed

van-de-Vijver, MJ, He, YD, Veer, LJvt, et al. A gene expression signature as a predictor of survival in breast cancer. New England Journal of Medicine. 2002;347(25):1999–2009.CrossRefGoogle ScholarPubMed

vanHouwelingen, HC, Bruinsma, T, Hart, AAM, van'tVeer, LJ, Wessels, LFA. Cross-validated Cox regression on microarray gene expression data. Statistics in Medicine. 2006;25:3201–3216.CrossRefGoogle Scholar

van't-Veer, LJ, Dai, H, Vijver, MJvd, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.CrossRefGoogle Scholar

vanWieringen, WN, Kun, D, Hampel, R, Boulesteix, AL. Survival prediction using gene expression data: a review and comparison. Computational Statistics and Data Analysis. 2009;53:1590–1603.CrossRefGoogle Scholar

Varma, S, Simon, R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006;7:91.CrossRefGoogle ScholarPubMed

Wang, SJ, O’Neill, RT, Hung, HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics. 2007;6:227–244.CrossRefGoogle ScholarPubMed

West, M, Blanchette, C, Dressman, H. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:11462–11467.CrossRefGoogle ScholarPubMed

Zhang, B, Tsiatis, AA, Laber, EB, Davidian, M.A robust method for estimating optimal treatment regimens. Biometrics 2012 (Online May 2, 2012).CrossRefGoogle Scholar

Zhao, YD, Dmitrienko, A, Tamura, R. On optimal designs of clinical trials with a sensitive subgroup. Statistics in Biopharmaceutical Research. 2010;2(1):72–83.CrossRefGoogle Scholar